JP2015518835A5 - - Google Patents

Download PDF

Info

Publication number
JP2015518835A5
JP2015518835A5 JP2015512776A JP2015512776A JP2015518835A5 JP 2015518835 A5 JP2015518835 A5 JP 2015518835A5 JP 2015512776 A JP2015512776 A JP 2015512776A JP 2015512776 A JP2015512776 A JP 2015512776A JP 2015518835 A5 JP2015518835 A5 JP 2015518835A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
peptide
seq
administered
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2015512776A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015518835A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/041063 external-priority patent/WO2013173411A1/en
Publication of JP2015518835A publication Critical patent/JP2015518835A/ja
Publication of JP2015518835A5 publication Critical patent/JP2015518835A5/ja
Withdrawn legal-status Critical Current

Links

JP2015512776A 2012-05-16 2013-05-15 癌幹細胞を標的とした癌ワクチン Withdrawn JP2015518835A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261647615P 2012-05-16 2012-05-16
US61/647,615 2012-05-16
PCT/US2013/041063 WO2013173411A1 (en) 2012-05-16 2013-05-15 Cancer stem cell targeted cancer vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018008606A Division JP2018109004A (ja) 2012-05-16 2018-01-23 癌幹細胞を標的とした癌ワクチン

Publications (2)

Publication Number Publication Date
JP2015518835A JP2015518835A (ja) 2015-07-06
JP2015518835A5 true JP2015518835A5 (https=) 2016-07-07

Family

ID=49584234

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015512776A Withdrawn JP2015518835A (ja) 2012-05-16 2013-05-15 癌幹細胞を標的とした癌ワクチン
JP2018008606A Pending JP2018109004A (ja) 2012-05-16 2018-01-23 癌幹細胞を標的とした癌ワクチン
JP2020065482A Pending JP2020117519A (ja) 2012-05-16 2020-04-01 癌幹細胞を標的とした癌ワクチン
JP2022104015A Pending JP2022130585A (ja) 2012-05-16 2022-06-28 癌幹細胞を標的とした癌ワクチン
JP2024110688A Pending JP2024156682A (ja) 2012-05-16 2024-07-10 癌幹細胞を標的とした癌ワクチン

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018008606A Pending JP2018109004A (ja) 2012-05-16 2018-01-23 癌幹細胞を標的とした癌ワクチン
JP2020065482A Pending JP2020117519A (ja) 2012-05-16 2020-04-01 癌幹細胞を標的とした癌ワクチン
JP2022104015A Pending JP2022130585A (ja) 2012-05-16 2022-06-28 癌幹細胞を標的とした癌ワクチン
JP2024110688A Pending JP2024156682A (ja) 2012-05-16 2024-07-10 癌幹細胞を標的とした癌ワクチン

Country Status (16)

Country Link
US (3) US10485858B2 (https=)
EP (4) EP3536334B1 (https=)
JP (5) JP2015518835A (https=)
CA (2) CA3183703A1 (https=)
CY (1) CY1124512T1 (https=)
DK (1) DK3536334T3 (https=)
ES (2) ES2967342T3 (https=)
HR (1) HRP20211432T1 (https=)
HU (1) HUE056350T2 (https=)
LT (1) LT3536334T (https=)
PL (1) PL3536334T3 (https=)
PT (1) PT3536334T (https=)
RS (1) RS62406B1 (https=)
SI (1) SI3536334T1 (https=)
SM (1) SMT202100545T1 (https=)
WO (1) WO2013173411A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3183703A1 (en) 2012-05-16 2013-11-21 Stemline Therapeutics, Inc. Cancer stem cell targeted cancer vaccines
WO2018065623A2 (en) 2016-10-07 2018-04-12 Enterome Immunogenic compounds for cancer therapy
CN110022894B (zh) 2016-10-07 2024-01-19 恩特罗姆公司 用于癌症疗法的免疫原性化合物
WO2018065628A2 (en) 2016-10-07 2018-04-12 Enterome Microbiota sequence variants of tumor-related antigenic epitopes
US20210106652A1 (en) * 2018-04-11 2021-04-15 Enterome S.A. Immunogenic Compounds For Treatment Of Fibrosis, Autoimmune Diseases And Inflammation
HRP20230007T1 (hr) * 2018-04-11 2023-03-03 Enterome S.A. Antigenski peptidi, namijenjeni sprječavanju i liječenju raka
CN115605595A (zh) * 2020-02-05 2023-01-13 瓦克斯恩有限公司（Ae） 生存素与gm-csf的融合体、编码dna、重组表达载体、抗肿瘤疫苗及其应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
DE4121547A1 (de) 1991-06-28 1993-01-14 Daimler Benz Ag Mehrschichtisolierfolie
US6419931B1 (en) 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
US6162432A (en) 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
ATE161190T1 (de) 1991-10-07 1998-01-15 Biogen Inc Vorbeugungsmethode oder behandlung von, durch antigen-präsentierende zellen hervorgerufene, hautkrankheiten mittels inhibitoren der cd2/lfa-3 wechselwirkung
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
WO1996018409A1 (en) 1994-12-14 1996-06-20 The Scripps Research Institute In vivo activation of tumor-specific cytotoxic t cells
US5837231A (en) * 1996-06-27 1998-11-17 Regents Of The University Of Minnesota GM-CSF administration for the treatment and prevention of recurrence of brain tumors
WO2001058479A1 (en) 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
CA2671940A1 (en) 2000-02-23 2001-08-30 Cv Therapeutics, Inc. Identification of partial agonists of the a2a adenosine receptor
AU2002250236A1 (en) 2001-03-02 2002-09-19 Medimmune, Inc. Cd2 antagonists for treatment of autoimmune or inflammatory disease
CA2439852A1 (en) 2001-03-02 2002-09-12 Christine Dingivan Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists
FR2838742B1 (fr) 2002-04-23 2004-07-09 Inst Nat Sante Rech Med Epitopes t de l'antigene epha2
WO2004087758A2 (en) 2003-03-26 2004-10-14 Neopharm, Inc. Il 13 receptor alpha 2 antibody and methods of use
AU2004229501B2 (en) 2003-04-11 2011-08-18 Medimmune, Llc Recombinant IL-9 antibodies and uses thereof
JP2004353820A (ja) 2003-05-30 2004-12-16 Toyota Motor Corp トリポート型等速ジョイント部品およびトリポート型等速ジョイント
EP1651671A2 (en) 2003-07-30 2006-05-03 University Of Pittsburgh Of The Commonwealth System Of Higher Education Epha2 t-cell epitope agonists and uses therefor
EP1682173A4 (en) 2003-10-15 2007-10-31 Medimmune Inc EPHA2 VACCINE ON LISTERIA BASE
WO2005049073A2 (en) 2003-11-19 2005-06-02 Survac Aps Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients
US20050153923A1 (en) 2003-12-04 2005-07-14 Kinch Michael S. Targeted drug delivery using EphA2 or EphA4 binding moieties
US7612162B2 (en) 2004-09-21 2009-11-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific CTL response
ES2534752T3 (es) 2004-12-07 2015-04-27 Toray Industries, Inc. Nuevo péptido antigénico contra el cáncer y utilización del mismo
ES2523172T3 (es) * 2005-02-04 2014-11-21 Survac Aps Vacuna de péptido de survivina
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
CA2628255C (en) 2005-10-31 2016-04-19 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US8343461B2 (en) 2006-03-08 2013-01-01 Wake Forest University Health Sciences Molecular signature of cancer
ES2536426T3 (es) 2006-03-23 2015-05-25 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores
US8063063B2 (en) 2006-03-23 2011-11-22 Novartis Ag Immunopotentiating compounds
CA2698597A1 (en) 2006-09-07 2008-03-13 Stemline Therapeutics, Inc. Monitoring cancer stem cells
US20080118518A1 (en) 2006-09-07 2008-05-22 Cirrito Thomas P Cancer stem cell-targeted cancer therapy
CA2700436C (en) 2006-09-28 2017-04-18 John S. Yu Cancer vaccines and vaccination methods
CA2675521C (en) 2007-01-22 2016-04-26 Raven Biotechnologies Human cancer stem cells
CN101754768B (zh) 2007-07-19 2013-07-10 健康研究股份有限公司 用作癌症疫苗的存活蛋白肽
RS53782B1 (sr) * 2008-10-01 2015-06-30 Immatics Biotechnologies Gmbh Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera
WO2011100754A1 (en) 2010-02-15 2011-08-18 The Trustees Of The University Of Pennsylvania Live listeria-based vaccines for central nervous system therapy
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
CA2809362C (en) 2010-08-24 2020-03-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Educatn Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
US8801711B2 (en) * 2011-06-16 2014-08-12 Clifford T. Solomon Skull clamp system with pressure limiting and alarm systems
CA3183703A1 (en) 2012-05-16 2013-11-21 Stemline Therapeutics, Inc. Cancer stem cell targeted cancer vaccines

Similar Documents

Publication Publication Date Title
JP2015518835A5 (https=)
Juratli et al. Current status of local therapy in malignant gliomas—a clinical review of three selected approaches
MX2017014532A (es) Vacunas para el tratamiento y prevencion del cancer.
CR20160018A (es) Nueva inmunoterapia contra diversos tumores como el cáncer de pulmón, incluido el carcinoma de pulmón amicrocítico (nsclc)
MX384315B (es) Agente para el tratamiento y/o prevención de enfermedades asociadas con anormalidades inmunes.
EP4382164A3 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
WO2015193359A3 (en) Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll)
MX2013002207A (es) Vacunas contra el cancer cerebral basadas en peptido alfa 2 del receptor de interleucina 13.
WO2016105542A3 (en) Nanoparticle compositions and methods for immunotherapy
EP4253401A3 (en) Personalized immunotherapy against several neuronal and brain tumors
EP4223772A3 (en) Optimized factor viii gene
JP2015110588A5 (https=)
IN2014CH00391A (https=)
MX2016014414A (es) Vacuna de peptido que comprende un peptido ras mutante y un agente quimioterapeutico.
WO2017044803A8 (en) Expression vector delivery system and use thereof for inducing an immune response
MX2021002513A (es) Composicion que comprende desintegrina y metaloproteinasa con motivos tipo i de trombospondina 13 (adamts13) para administracion subcutanea.
PH12014501388A1 (en) A recombinant koi herpesvirus (khv) and vaccine for the prevention of a disease caused by khv
RU2016108808A (ru) Терапевтическое применение vegf-c и ccbe1
HK1207152A1 (en) Multivalent breast cancer vaccine
EP4253419A3 (en) A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer
WO2015054678A3 (en) Human papilloma virus therapeutic vaccine
JP2012102105A5 (https=)
WO2014160987A3 (en) Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
EP4321218A3 (en) Cancer stem cell targeted cancer vaccines
IN2014CH00390A (https=)